NasdaqGS:KRYSBiotechs
Why Krystal Biotech (KRYS) Is Up 8.0% After Surging VYJUVEK Revenue and Global Expansion
Krystal Biotech, Inc. recently reported third-quarter 2025 earnings, revealing net income of US$79.37 million and total revenue of US$97.8 million, reflecting substantial gains compared to the same period last year and continued global commercial expansion of its lead gene therapy, VYJUVEK.
Key milestones included successful launches of VYJUVEK in Germany, France, and Japan, high US reimbursement approvals, and regulatory steps that broadened the eligible patient population, highlighting...